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ABSTRACTS:  Diabetes mellitus is a heterogeneous disorder that affects cellular metabolism in variety of 
ways, and coagulation indices are reported to be adversely affected. In the current study prothrombin time (PT) 
and activated partial thromboplastin time (APTT) were investigated in treated and untreated diabetics as well as 
in non diabetic controls. Using clot based assay technique, PT was 20.620± 2.849, 16.720±2.339, and 14. 
920±1.209 in   untreated, treated and in non diabetic controls respectively. There were statistically significant 
differences (p<0.05) between the untreated and treated diabetics as well as between untreated and non 
diabetic controls. APTT was 58.460±4.146, 43.260±5.587 and 41.380±4.295 in untreated, treated and in non 
diabetic controls respectively. There is statistically significant difference (p>0.05) between untreated and treated 
diabetics (p<0.05).Value of treated and controls are not significantly difference (p>0.05). Our finding suggest an 
abnormal PT and APTT in untreated patients with diabetes mellitus.  
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INTRODUCTION 
Diabetes mellitus is a common endocrine disease of 
multiple aetiology   (Oguntona and Amballi, 2005; 
Ogunkolo and Alebiosu, 2006). It is characterised by 
chronic hyperglycaemia with subsiquent disturbances 
of carbohydrates, fat and protein metabolism (Momo 
et al., 2006). Excessive blood glucose produces the 
classical symptoms such as polydipsia (increased 
thirst), polyuria (frequent urination) and polyphagia 
(increased hunger) (Cooke and Plotnick , 2008). In 
Nigeria and the world at large, Diabetes is a major 
health problem with about 90% of diabetic patients 
having non insulin type II while about 10% have 
insulin dependent (Ohwworiola et al., 1998). 
 
Body of evidence suggest that certain haematological 
indices are altered in patients with diabetes mellitus 
(Dallatu et al., 2010).  In patient with diabetes 
mellitus, persistent hyperglycaemia exposes red 
blood cells (RBCs) to elevated glucose concentration,   
thus resulting in glycalation of haemoglobin, 
prothrombin, fibrinogen and other proteins involved in 
clotting mechanisms (Selvin et al., 2010). The 
glycation results in the incomplete activation and 
function of the clotting cascade (Qin, et al., 2004). 
Glycation of intrinsic and extrinsic clotting proteins will 
decrease the availability of these proteins which 
affect the clotting capacity (Lippi et al., 2009). 
 
Prothrombin time (PT) and activated partial 
thromboplastin time (APTT) are haematological 
indices that give an insight into the coagulation status 
of patients (Hinchcliff et al., 2004). Divided into 3 
pathways of intrinsic, extrinsic and common, these 
factors collectively play a central role in arresting 
bleeding disorder (Merlo et al., 2002, Kucharska-
Newton et al., 2009). 
 
 The blood contains about a dozen clotting factors 
(Alesci et al., 2008). These factors are proteins that 
exist in the blood in an inactive state, but can be 
called into action when tissues or blood vessels are 
damaged (Alesci et al., 2008). Blood clotting is the 
transformation of liquid blood into a semisolid gel.  
Clots are made from fibers (polymers) of a protein 
called fibrin. Fibrin monomers come from an inactive 
precursor called fibrinogen. Also called Factor I, 
fibrinogen play critical role in blood viscosity. 
Increased concentration of fibrinogen 
(hyperfibrinogenemia) in uncontrolled NIDDM 
patients is implicated in vascular damage induction 
(Zachary and Bloomgarden, 2011). 
 
In the laboratory, measurement of PT, APTT, and 
fibrinogen concentration are the most commonly 
employed laboratory tests in patients with a 
suspected coagulopathy (Furlanello et al., 2006). 
Prothrombin time is a laboratory screening test used 
to detect disorders involving the activity of the factors 
I, II, V, VII, and X of the extrinsic and common 
pathways (Hinchcliff et al., 2004). Activated partial 
thromboplastin time is used to screen for 
abnormalities of the intrinsic and common clotting 
systems and to monitor the anticoagulant effect of 
circulating heparin. It measures the activities of 
factors I, II, V, VIII, IX–XI, and XII of the intrinsic and 
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Changes in these proteins favour the development of 
hyper-coagulable and pro-thrombotic state, which 
may in turn enhance cardiovascular risk by increasing 
the likely hood of developing an occlusive thrombus 
within a coronary/cerebral artery contributing to the 
development of atherosclerotic lesion (Dunn and 
Grant, 2005). PT and APTT can therefore be used to 
assess the risk of clotting complications in patients 
with diabetes mellitus  although modern coagulation 
diagnostic test are becoming more sophisticated, PT 
and APTT are still important basic examinations in 
clinical laboratories (Ng, 2009).  
 
The current study was therefore designed to evaluate 
the PT and APTT in treated, untreated and in non 
diabetics control subjects.  
 
MATERIALS AND METHODS 
One hundred and fifty (150) diabetic patients of 50 
treated, 50 untreated and 50 apparently healthy non 
diabetic controls where selected for the research. 
They were recruited from patients attending diabetes 
clinic of Usmanu Danfodiyo University Teaching 
Hospital, Sokoto, North West Nigeria. Institutional 
ethical clearances were obtained and an informed 
consent form was explained to each participant 
before they signed the consent. Specimens for PT 
and APTT measurement were obtained by vein 
puncture after a 12 hour fast. PT and APTT were 
measured using calcium rabbit brain thromboplastin 
and kaolin platelet substitute techniques (DIAGEN 
DIAGNOSTIC REAGENT LTD, OXON, U.K). Briefly, 
PT was assayed with two hundred microlitre of 
calcum rabbit brain thromboplastin reagent placed in 
a clotting tube and incubated in a water bath at 37o C 
for 2 minutes. Hundred microlitre of plasma is then 
added and a stop watch started. The tube is gently 
tilted at regular interval and the watch was stopped 
when the clot formation was observed.  For APTT, 
two hundred microlitre of kaolin platelet substitute 
mixture was placed in a clotting tube and incubated in 
a water bath at 37oC for 2 minutes. One hundred 
microliter of plasma was then added and the tube 
was gently tilted at interval for exactly two minutes. 
One hundred microliter of calcium chloride (pre-
incubated at 37O C) was then added and a stop watch 
started. The tube was tilted at intervals and the time 
for clot formation was recorded. Our laboratory has a 
reference ranges for PT and APTT, as 10-16 seconds 
and 30-48 seconds respectively.  
 
Statistical Analysis 
Data processing was done using one way ANOVA 
Graphic Pad Instant software package, Sandiego, 
U.S.A. The result was expressed as mean ± SD. The 
paired t-test was used to determine the significant 




Result of prothrombin time (PT) and activated partial 
thromboplastin time (APTT) study was shown in 
Table 1. For PT, there are statistically significant 
differences between the untreated and treated 
diabetics as well as between untreated and non 
diabetic controls (p<0.05). The difference between 
treated and non diabetics controls is not significant.  
For APTT, there is statistically significant difference 
(P<0.05) between untreated and treated diabetics. 
The difference between treated and non diabetic 
controls is not statistically significant (p>0.05).  
 
Table 1:  Prothrombin Time (PT) and Activated 
Partial Thromboplastin Time (APTT) 
concentrations of study subjects in Sokoto, 
Nigeria  
GROUPS PT(seconds) APTT(seconds) 
Untreated diabetic 20.620±2.849* 58.460±4.146* 
Treated diabetics               16.720±2.339, 43.260±5.587 
Control  14.920±1.209 41.380±4.295 
Value are Mean ± SD *significantly different (P<0.05) 
when compared with non diabetic controls using Graphic 
Pad Instant software, Sandiego, U.S.A 
 
DISCUSSION 
Diabetes mellitus is a heterogeneous disease 
affecting metabolism of various compounds including 
carbohydrates, lipids and proteins which also impairs 
biological processes such as coagulation 
homeostasis that causes vascular thrombotic 
problems (Carr, 2001; Hameed et al., 2002).  
 
The circulatory disturbances in diabetes are 
characterized by alternation in platelet count and 
activity, coagulopathy, fibrinolytic aberration, 
haemorrheologic factors and changes in endothelial 
metabolism (McFarlane, 1997). In patient with 
diabetes mellitus, persistent hyperglycaemia exposes 
red blood cells (RBC) to elevated glucose 
concentration,   thus resulting in glycation of 
haemoglobin, prothrombin, fibrinogen and other 
protein involved in clotting mechanisms (Selvin  et al., 
2010). 
 
In the current study, it was observed that non-diabetic 
individuals and treated diabetics have a prothrombin 
time (PT) value within the reference range of 10-16 
as against a value of 20.620±2.849 seen in untreated 
diabetics. This is in agreement with the findings of 
(Alao et al., 2010). In patients with diabetes mellitus, 
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abnormalities in coagulation haemostasis, platelets 
dysfunction and reduced activity of fibrinolytic system 
can collectively accelerate atherogenesis in diabetic 
patients (Carr, 2001). Merlo et al., (2002) reported an 
increase in tissue factor (TF) and subsequent 
conversion of inactive factor vii to active factor vii 
which triggers the extrinsic pathway .  This will lead to 
an increase in PT as reported here. Diabetic 
hypertriglyceridemia, the additional risk factor for 
cardiovascular problems, in addition to increased 
levels of TF and an activated factor VII gives a bad 
prognosis for serious fatal ischemic heart disease 
(Kucharska-Newton et al., 2009). Hyperglycemia has 
been considered to be the causative factor of these 
abnormalities in coagulation pathways, and exposes 
patient with diabetes to macrovascular mortality 
(Standl et al., 1996). Several studies have shown that 
levels of PT are increased in both type 1 and type 2 
diabetic patients and that glycaemic control 
normalizes PT levels in diabetic patients (Standl et al, 
1996).  
 
 In the current study, a significant elevation of APTT 
was recorded in untreated diabetics when compared 
with treated diabetics (p<0.05). This is similar to the 
findings of Hassan, (2009) and Maysam et al., 
(2011). Increased plasma levels of PT and APTT are 
consistent with abnormal coagulation mechanism and 
may be interpreted as a tendency to bleeding and 
cardiovascular disorders (Hassan, 2009). Increase in 
the intrinsic pathway proteins, and activation of blood 
coagulation mechanism are  consistent in diabetics 
(Berliner et al., 2002; Eteng et al., 2008;  Behnam  et 
al., 2010).  
 
The pathogenetic mechanism of the clotting 
activation in diabetes is not completely clear. 
Perturbance of components of the anticoagulant 
system associated with hyperglycaemia may play an 
important role as exemplified in hyperglycaemia 
induced depression of biological activity of the 
anticoagulant proteins such as AT-III. This, in addition 
to non enzymatic glycation, are suggested to be the 
causative factors of  AT-III dysfunction (Hassan, 
2009).  
 
The presents finding and previous studies (Hu, et al., 
1998). Thrombotic and hypercoagulable 
complications in diabetes patients are introductions to 
vascular and cardiovascular complications (Gabazza 
et al., 1996). A prognostic clue in the simultaneous 
measurement of factors I, II, V, VII, X for PT and 
factors I, II, V, VII, X, Phospholipids and calcium for 
APTT and fibronogen could be initially prescribed. 
Since these factors show critical and more specific 
alterations in the early stages of diabetes disease, by 
giving an awfully bad prognosis in coagulation 
disturbance.  Therefore, hypercoagulable state 
management may have a preventive value in 
subsequent vascular complications in patients with 
diabetes mellitus 
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